Lilly

LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT BRITAIN FOR MIRIKIZUMAB (OMVOH) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Basingstoke, UK - 28 June 2023 - Eli Lilly and Company announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for mirikizumab (OMVOH) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were...

(800) 545-5979